ライフサイエンスコーパス: bisphosphonate

1 ly treated with ibandronate, a commonly used bisphosphonate.

2 uires aggressive intravenous hydration and a bisphosphonate.

3 enhanced by covalent functionalization with bisphosphonate.

4 We did not have information on intravenous bisphosphonates.

5 ine T-scores of less than -2.0 also received bisphosphonates.

6 ab may delay worsening of pain compared with bisphosphonates.

7 mperfecta are often treated with intravenous bisphosphonates.

8 a potential adjuvant benefit of intravenous bisphosphonates.

9 , hormone therapy, and the administration of bisphosphonates.

10 patients were stratified based on the use of bisphosphonates.

11 hocardiogram, 323 patients (38%) were taking bisphosphonates.

12 as applied for the probability of the use of bisphosphonates.

13 pecifically queried about the regular use of bisphosphonates.

14 risk factor, and six (26%) had received oral bisphosphonates.

15 te, and data are extremely limited for other bisphosphonates.

16 e to AFFs in patients treated with long-term bisphosphonates.

17 calcium channel blockers, beta-blockers, and bisphosphonates.

18 has osteopenia, should she be treated with a bisphosphonate?

19 no evidence of benefit from the addition of bisphosphonates (1.03 [0.89-1.18]; p=0.724) or zoledroni

20 The PI3K (phosphatidylinositol-4,5-bisphosphonate 3-kinase) enzyme has a pivotal role in th

21 mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypep

22 ith parathyroidectomy (4.2% at <2 years) and bisphosphonates (3.6% at <2 years) and declined progress

23 methyl 2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate (7), specifically expanded gammadelta T c

24 mice are also enhanced on administration of bisphosphonate, a class of drugs frequently used for the

25 scuss these considerations in the context of bisphosphonate active comparator initiation and disconti

26 nge in dosage, infusion time, or interval of bisphosphonate administration is required.

27 Bisphosphonates after KT were more frequently used in gr

28 ion was inhibited pharmacologically with the bisphosphonate alendronate.

29 integrin alpha4beta1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affini

30 Bisphosphonates also had no impact on survival or freedo

31 We describe the synthesis of PP-IP bisphosphonate analogues (PCP-IPs), which are resistant

32 Acyclic nucleoside bisphosphonates (ANbPs) have previously been shown to be

33 Conjugates incorporating a bisphosphonate and an antibiotic for bone-targeted deliv

34 model, we assessed the effect of established bisphosphonate and anti-RANKL therapies on bone metastas

35 ct on tooth-extraction wound healing between bisphosphonate and PTH therapies.

36 Both bisphosphonates and denosumab improve BMD in men with no

37 Both bisphosphonates and denosumab, through different pathway

38 aluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort

39 sk of oesophageal cancer in women prescribed bisphosphonates and is based on the largest number of ex

40 Newer agents, notably bisphosphonates and metformin, have shown promise in obs

41 To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuv

42 erve an association between long-term use of bisphosphonates and risk of colorectal cancer.

43 The affinity between bisphosphonates and the apatite structure of bone metast

44 Although bisphosphonates and tumor necrosis factor-alpha inhibito

45 sphonates, post-treatment residual effect of bisphosphonates, and a potential adjuvant benefit of int

46 nations of potassium citrate, thiazides, and bisphosphonates, and correcting bone and urinary abnorma

47 fects of anti-resorptive drugs, particularly bisphosphonates, and the absence of clear evidence in su

48 ncreased in frequency with the advent of new bisphosphonates, antitumor necrosis factor biologic agen

49 target bone without requiring a traditional bisphosphonate are synthesized.

50 Bisphosphonates are a common treatment to reduce osteopo

51 Continuous users of oral bisphosphonates are at a higher risk of developing wet A

52 Bisphosphonates are common medications used for the trea

53 hip, nonvertebral, and vertebral fractures; bisphosphonates are commonly used as first-line treatmen

54 Linear 2-alkylaminoethyl-1,1-bisphosphonates are effective agents against proliferati

55 Bisphosphonates are indicated for the treatment of osteo

56 Isoprenoid-substituted bisphosphonates are known to serve as inhibitors of the

57 Bisphosphonates are routinely used in the treatment of m

58 Bisphosphonates are the frontline therapy for osteoporos

59 Bisphosphonates are the most widely prescribed pharmacol

60 Bisphosphonates are the standard of care for reducing th

61 Bisphosphonates are therapeutic agents in the treatment

62 Bisphosphonates are thought to act through the osteoclas

63 Statins and bisphosphonates are two distinct classes of isoprenoid p

64 Bisphosphonates are used for the treatment of bone metas

65 racture risk among THR patients who received bisphosphonates as primary prevention (hazard ratio [HR]

66 antiresorptive agents such as denosumab and bisphosphonates, as well as complementary approaches suc

67 Bisphosphonate-associated osteonecrosis of the jaw (BRON

68 efore, in periodontal tissues pre-exposed to bisphosphonate, bacterial infection at tooth extraction

69 A related reaction occurs for the bisphosphonate-based drug, risedronic acid, in the prese

70 metric experiments show that both lipophilic bisphosphonates bind to GGPPS with, on average, a DeltaG

71 The traditional bisphosphonate (BP) alendronate (Aln) or IG9402, a BP an

72 The average number of bisphosphonate (BP) infusions was significantly higher i

73 The association between oral bisphosphonate (BP) intake and colorectal cancer (CRC) r

74 Purpose To assess whether bisphosphonate (BP) use is associated with decreased bre

75 Bisphosphonates (BPs) and low-dose doxycycline (LDD) hav

76 Data on the effect of oral bisphosphonates (BPs) on risk of upper gastrointestinal

77 Bisphosphonates (BPs) should be considered in all patien

78 NJ) commonly occurs in individuals receiving bisphosphonates (BPs) with clinical manifestations of th

79 te is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on

80 l fractures and initiation of treatment with bisphosphonates, calcitonin, or raloxifene were treated

81 Bisphosphonates can mimic the pyrophosphate leaving grou

82 Adjuvant use of bisphosphonates can reduce the incidence of bone metasta

83 Here we describe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utili

84 302.5 events per 1000 patients treated with bisphosphonates compared with 206.1 events per 1000 pati

85 d 85.5 events per 1000 patients treated with bisphosphonates compared with 55.9 events per 1000 patie

86 riethylene glycol to form triethylene glycol-bisphosphonate conjugates 4 and 5 as model compounds for

87 only 0.5 kcal mol(-1) worse than the parent bisphosphonates, consistent with the observation that co

88 via Mg(2+) to the same site as seen in other bisphosphonate-containing structures.

89 There is high-strength evidence that bisphosphonates, denosumab, and teriparatide reduce frac

90 We hypothesized that a bisphosphonate derivative of enoxacin, bis-enoxacin (BE)

91 ies have focused on agents such as warfarin, bisphosphonates, diltiazem and others, which are primari

92 ospective analysis of older female patients, bisphosphonates do not have a significant impact on the

93 Thus, bisphosphonate drastically inhibited bone remodeling.

94 the great potential for non-invasive in vivo bisphosphonate drug tracking.

95 osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the migration of human br

96 lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and di

97 inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating nonskeleta

98 ome barriers to cell penetration of existing bisphosphonate drugs in this and other systems by simple

99 The treatment of bisphosphonate drugs, either alendronate (ALN) or zoledr

100 mammalian isoprenoids and the key target of bisphosphonate drugs.

101 Introduction of bisphosphonates during the past 20 years has targeted bo

102 Pivoxil bisphosphonate esters enter cells where esterases conver

103 The bisphosphonate esters stimulated gammadelta T cells to s

104 mined that the administration of PPi and the bisphosphonate etidronate to Abcc6(-/-) mice fully inhib

105 estimated ONJ incidence and odds ratios from bisphosphonate exposure and other risk factors using a k

106 enopausal osteoporosis who had taken an oral bisphosphonate for at least 3 years before screening and

107 ocetaxel or standard of care with or without bisphosphonates for men with high-risk localised or meta

108 Of 17 trials of bisphosphonates for men with M0 disease, survival result

109 ven eligible randomised controlled trials of bisphosphonates for men with M1 disease.

110 ng followed by selective treatment with oral bisphosphonates for those diagnosed with osteoporosis is

111 rosis, annual BMD screening followed by oral bisphosphonates for those with osteopenia, and universal

112 One-time BMD screening followed by oral bisphosphonates for those with osteoporosis or osteopeni

113 Rs for annual BMD screening followed by oral bisphosphonates for those with osteoporosis, annual BMD

114 In the reaction, the bisphosphonate functional groups -C(PO(3)H(2))(2)(OH) in

115 as monitored from a thin, dispersed layer of bisphosphonate-functionalized nanotags on a bone sample,

116 Bisphosphonates (generic) and denosumab reduce the risk

117 We reported a series of triazole bisphosphonate GGDPS inhibitors, of which the most poten

118 d water-soluble prodrugs which incorporate a bisphosphonate group as a bone targeting ligand, doxorub

119 ndronate (ALN), an influential member of the bisphosphonate group, is known to enhance osteoblastogen

120 Alendronate (ALN), a member of the amino-bisphosphonate group, is known to enhance periodontal ti

121 Ps conjugated with alendronate (ALD), of the bisphosphonate group.

122 phorus dendrimers bearing 48 (G3) or 96 (G4) bisphosphonate groups on their surface.

123 howed that tissue from patients treated with bisphosphonates had deficits in fracture toughness, with

124 Use of oral bisphosphonates has been associated with a decreased ris

125 The combining of anabolic agents with bisphosphonates has not improved efficacy.

126 ixture of homogeranyl and homoneryl triazole bisphosphonates has previously demonstrated potent activ

127 y believed to be exclusively associated with bisphosphonates, has been implicated in recent reports w

128 Bisphosphonates have a widespread indication for osteopo

129 Bisphosphonates have been suggested to slow this progres

130 Bisphosphonates have been used to treat Duchenne muscula

131 Bisphosphonates have benefits in breast cancer and multi

132 wounds is decreased in the presence of amino-bisphosphonates; however, the mechanism remains unknown.

133 Bisphosphonates improve pain in patients with bony metas

134 0 [88%] of 3109 men) showed that addition of bisphosphonates improved survival (0.88 [0.79-0.98]; p=0

135 Osteoclast inhibition with any of several bisphosphonates improves bone mineral density, a surroga

136 ith recombinant human IGF-1 in one study and bisphosphonates in another--increased BMD, but not to th

137 The role of adjuvant bisphosphonates in early breast cancer is uncertain.

138 justed OR for wet AMD among regular users of bisphosphonates in the 1, 2, and 3 years prior to the in

139 Randomized trials have studied bisphosphonates in the adjuvant setting of early breast

140 ate, an orally administered third-generation bisphosphonate, in children with the disease.

141 oncerns have been raised as to the safety of bisphosphonates; in particular a possible link between b

142 m concentration in animals pretreated with a bisphosphonate, indicating that the increase did not res

143 at alendronate, a member of the N-containing bisphosphonates, indirectly inhibits osteoblast function

144 a conclusively with the etio-pathogenesis of bisphosphonate-induced osteonecrosis of the jaw (BONJ).

145 ty may be related to the pathogenesis of the bisphosphonate-induced osteonecrosis of the jaw.

146 risk of ocular inflammatory side effects of bisphosphonate infusions and the need for referral to an

147 Bisphosphonates inhibit osteoclast differentiation/funct

148 At approximately 100% efficacy, bisphosphonates inhibited cancer progression while, in c

149 ted from MLO-Y4 osteocyte cells treated with bisphosphonates inhibited the anchorage-independent grow

150 mediates, 3- to 4-fold, upstream of DMADP in bisphosphonate-inhibited leaves, but the DMADP pool was

151 A bisphosphonate inhibitor binds to the same site.

152 mpared with approximately 0.5 microM for the bisphosphonate inhibitor, zoledronate).

153 We used bisphosphonate inhibitors, alendronate and zoledronate,

154 Higher risk of ONJ began within 2 years of bisphosphonate initiation and increased four-fold after

155 Bisphosphonate injections in Ank (+/+) mice replicate th

156 lth Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of devel

157 ts that the absolute risks for ONJ from oral bisphosphonates is low.

158 The critical chemical feature of bisphosphonates is the amino moiety, because its loss sw

159 Zoledronic acid, a potent bisphosphonate, is commonly administered to patients wit

160 alogous Co(II)2 complex with a CEST-inactive bisphosphonate ligand exhibits no such pH response, conf

161 Functionalization with a bisphosphonate ligand results in significant binding to

162 tra(carboxamide) and/or hydroxyl-substituted bisphosphonate ligands.

163 Use of bisphosphonates lowered the fracture risk among THR pati

164 However, bisphosphonates may oversuppress remodelling resulting i

165 Bisphosphonates may prevent or treat the bone loss promo

166 Evidence showed that bisphosphonates may slow loss of BMD among transplant re

167 Findings of NSABP B-34 suggest that bisphosphonates might have anticancer benefits for older

168 yield synthesis of a novel, small molecule, bisphosphonate-modified trans-cyclooctene (TCO-BP, 2) th

169 Nitrogen-containing bisphosphonates (N-BP), including zoledronic acid (ZOL)

170 flection at osteonal boundaries than that of bisphosphonate-naive patients.

171 Nitrogen bisphosphonates (NBPs) are commonly prescribed for osteo

172 Nitrogen-containing bisphosphonates (NBPs) are taken by millions for bone di

173 Here we report the self-assembly of zinc bisphosphonate NCPs that carry 48 +/- 3 wt% cisplatin pr

174 have now explored the potential efficacy of bisphosphonates, nonhydrolyzable PPi analogs, in prevent

175 val and overall survival (OS), making it the bisphosphonate of choice for newly diagnosed myeloma pat

176 ratios (HRs) of the effects of docetaxel or bisphosphonates on survival (time from randomisation unt

177 this study was to investigate the impact of bisphosphonates on the progression of aortic stenosis.

178 study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer.

179 oth extractions are typically on either oral bisphosphonate or parathyroid hormone (PTH) therapy.

180 acid) (PLGA), polyethylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand).

181 per 0.1 increment; p = 0.007) and the use of bisphosphonates (OR: 3.57, 95% CI: 1.14 to 10.80 p = 0.0

182 steoclast inhibition with zoledronic acid (a bisphosphonate) or with denosumab (a monoclonal antibody

183 categories including hormonal, chemotherapy, bisphosphonates, or immunotherapy).

184 age at the initiation of AI therapy, type of bisphosphonates, post-treatment residual effect of bisph

185 DINGS: Design-A case control study comparing bisphosphonate prescribing in cases of upper GI cancer f

186 y increased in women who had had one or more bisphosphonate prescriptions, odds ratio 1.54 (95% CI 1.

187 Antiresorptive treatments such as bisphosphonates prevent and counteract these side-effect

188 Bisphosphonates prevent skeletal-related events in patie

189 Using a similar approach, we synthesized bisphosphonate prodrugs and found that they efficiently

190 Therefore, bisphosphonate prodrugs could enhance the effectiveness

191 le peptide-linked conjugate for targeting of bisphosphonate prodrugs to bone and slow release liberat

192 ly elaborated to the pyrido[2,3-d]pyrimidine bisphosphonates (PYPY-BPs).

193 Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in

194 Bisphosphonate-related osteonecrosis of the jaw (BRONJ)

195 uggest that periodontitis is associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ).

196 dverse effect on specific sites, such as the bisphosphonate-related osteonecrosis of the jaw.

197 Bisphosphonates represent a class of pharmacologic agent

198 ed isoflavones in various proportions) and a bisphosphonate (risedronate).

199 orosis, diagnosed in 2004, she received oral Bisphosphonates (Risedronate) from 2004 until 2007 follo

200 Treatment with multiple statins, bisphosphonates, squalene synthase inhibitors, and small

201 Present bisphosphonates stimulate gammadelta T cells but were de

202 )](2+)* followed by (1)O(2) oxidation of the bisphosphonate substituent.

203 Nitrogen-bisphosphonates such as zoledronic acid (ZOL) trigger se

204 is common practice in patients treated with bisphosphonates, such as those who fracture while on the

205 Bisphosphonates suffer from poor "drug-like" properties

206 efits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab

207 an be used to monitor the effect of stopping bisphosphonate therapy (eg, to identify a threshold abov

208 Case reports and cohort studies have linked bisphosphonate therapy and osteonecrosis of the jaws (ON

209 Bisphosphonate therapy and rank-ligand monoclonal antibo

210 n lymphoma (71.1% vs. 59.3%; P < 0.001), and bisphosphonate therapy for multiple myeloma (62.1% vs. 5

211 the jaw after suspended oral and intravenous Bisphosphonate therapy implicating that the biologic the

212 ineral density (BMD) screening and selective bisphosphonate therapy in women with osteoporosis or ost

213 teopenia; annual BMD screening and selective bisphosphonate therapy in women with osteoporosis or ost

214 These findings suggest that bisphosphonate therapy is effective at reducing perforat

215 Oral bisphosphonate therapy was started if DXA hip T scores w

216 patient interviews for collection of data on bisphosphonate therapy, demographics, co-morbidities, an

217 onecrosis of the jaw (ONJ), a side-effect of bisphosphonate therapy, is characterized by exposed bone

218 ubstantial benefit for patients who received bisphosphonate therapy.

219 e of a reduction in risk of a DFS event with bisphosphonate therapy.

220 y posttransplant may influence the impact of bisphosphonate therapy.

221 th osteoporosis or osteopenia; and universal bisphosphonate therapy.

222 stmenopausal osteoporosis transitioning from bisphosphonate therapy.

223 here were 198 cases of wet AMD on continuous bisphosphonate therapy.

224 A new series of thienopyrimidine-based bisphosphonates (ThP-BPs) were identified that inhibit h

225 e no studies evaluating the influence of the bisphosphonate tiludronic acid (TIL) on periodontitis.

226 udy is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommende

227 linicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fractur

228 istic repurposing of existing compounds (eg, bisphosphonates) to one driven by advances in fundamenta

229 Furthermore, bisphosphonate-treated bone demonstrated reduced tensile

230 of young, treatment-naive osteoporosis, and bisphosphonate-treated cases were investigated in femora

231 Bone from bisphosphonate-treated fracture patients exhibited fewer

232 Oral and intravenous bisphosphonate-treated ONJ sites had reduced numbers of

233 mechanical properties of bone biopsies from bisphosphonate-treated patients with AFFs to those from

234 and nanoindentation showed that tissue from bisphosphonate-treated women with atypical fractures was

235 s harder and more mineralized than that from bisphosphonate-treated women with typical osteoporotic f

236 based on fracture morphology and history of bisphosphonate treatment [+BIS Atypical: n = 12, BIS dur

237 Previous bisphosphonate treatment attenuates the bone-forming eff

238 Collectively, these results suggest that bisphosphonate treatment may be beneficial by a dual eff

239 Analysis of our data suggests that bisphosphonate treatment may delay oral epithelial heali

240 ructural and mechanical properties following bisphosphonate treatment may foster resistance to fractu

241 he unusual fracture morphology suggests that bisphosphonate treatment may impair toughening mechanism

242 This paper aims to investigate the effect of bisphosphonate treatment on microstructure and mechanica

243 Oral bisphosphonate treatment was assumed, with a base-case a

244 s associated with reduced fracture risk, and bisphosphonate treatment was not superior to observation

245 In combined fosmidomycin/bisphosphonate treatment, pathway intermediates accumula

246 Potential risk factors include bisphosphonate treatment, steroid treatment, osteoporosi

247 of ovariectomized mice, which was blocked by bisphosphonate treatment.

248 ical osteoporotic fractures with and without bisphosphonate treatment.

249 We found that bisphosphonate treatments significantly reduced minerali

250 A meta-analysis of adjuvant bisphosphonate trials is suggested before recommendation

251 nconsistent for formal meta-analyses for the bisphosphonate trials.

252 As an example, bisphosphonate trimethyl ester 3a and P,P'-dimethyl este

253 hen cancer patients (n = 143) were excluded, bisphosphonate use (OR = 7.2 {2.1-24.7}), suppuration (O

254 ncology Group performance status (0-1 vs 2), bisphosphonate use (yes vs no), and urinary N-telopeptid

255 There was no association between bisphosphonate use and colorectal cancer within strata o

256 study showed an inverse association between bisphosphonate use and colorectal cancer.

257 ression analyses tested associations between bisphosphonate use and other risk factors with ONJ.

258 nates; in particular a possible link between bisphosphonate use and upper gastrointestinal (GI) cance

259 As an example, we explore the effect of bisphosphonate use on disease-free survival (DFS) using

260 ing fitted Cox models to study the effect of bisphosphonate use on the risk of fracture postsurgery.

261 Bisphosphonate use reduced the post-THR risk of fracture

262 The rate ratio for wet AMD for continuous bisphosphonate use was 1.99 (95% CI: 1.41-2.79).

263 The mean duration of bisphosphonate use was 3.1 +/- 2.6 years.

264 lth interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of

265 In conclusion, we found that oral bisphosphonate use was associated with a decreased odds

266 prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically s

267 In addition, bisphosphonate use was identified among patients undergo

268 Bisphosphonate use was strongly associated with ONJ (odd

269 The sensitivity and PPV for bisphosphonate use were both 80% (95% confidence interva

270 Both IV and oral bisphosphonate use were strongly associated with ONJ.

271 otal alkaline phosphatase level, and current bisphosphonate use, then randomly assigned (2:1) to rece

272 baseline pain, extraskeletal metastases, and bisphosphonate use, were randomly assigned in a 1:1 rati

273 of oesophageal cancer linked to duration of bisphosphonate use.

274 there is a newly recognized adverse event of bisphosphonate use: atypical subtrochanteric femur fract

275 Bisphosphonates used for treatment inhibit bone resorpti

276 ation of antiresorptive medications, such as bisphosphonates, used in the treatment of bone malignanc

277 the risk of gastric or oesophageal cancer in bisphosphonate users and one finding a small but signifi

278 esophageal and gastric cancer development in bisphosphonate users compared to non-users.

279 ients received treatment with calcimimetics, bisphosphonates, vitamin D, or phosphate supplementation

280 age-adjusted HR for women who regularly used bisphosphonates was 0.92 (95% CI, 0.73 to 1.14) and was

281 Ever use of bisphosphonates was associated with reduced endometrial

282 stronger inverse association for ever use of bisphosphonates was observed for men (OR 0.63; 95% CI: 0

283 ductoisomerase, alone or in combination with bisphosphonates was used to inhibit carbon input into DX

284 steopenia, and universal treatment with oral bisphosphonates were $87,300, $129,300, and $283,600 per

285 Patients with oral bisphosphonates were 15.5 (CI, 6.0-38.7) more likely to

286 steopenic and osteoporotic patients, whereas bisphosphonates were associated with increased fracture

287 Bisphosphonates were effective in increasing BMD, but no

288 Results Adjuvant bisphosphonates were found to reduce bone recurrence and

289 Participants who had ever used oral bisphosphonates were less likely than non-users to be di

290 were each reported by over 15% of women, and bisphosphonates were reported by 4.5%.

291 Considering low bioavailability of bisphosphonates when administered orally, subsequent stu

292 e pathways influenced by nitrogen-containing bisphosphonates, which are associated with improved surv

293 also include the administration of drugs as bisphosphonates, which reduce the formation of circulati

294 an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile.

295 sed controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensiti

296 The inhibitory capacity of bisphosphonates, with mechanistic implications, was conf

297 s 0 to 2 and clinical decision to treat with bisphosphonates within 3 months of randomisation were ra

298 The potent nitrogen-containing bisphosphonate zoledronate inhibits farnesyl pyrophospha

299 in Sprague Dawley rats (n = 30), and either bisphosphonate (zoledronate [Zol]), PTH, or saline (vehi

300 These agents are the bisphosphonate zoledronic acid and the monoclonal antibo

301 ethyl-glutaryl (HMG)-CoA reductase and the N-bisphosphonate zoledronic acid monohydrate, an inhibitor